6 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... HF outcomes in HFrEF ... HF outcomes in HFrEF ... visualabstract #table
Oral Antihypertensive Medications - Selection by Comorbidities
Comorbidities: 
 • Stable Angina, HFpEF, HFrEF, AFib, TAA/Marfan, Aortic
Comorbidities: • Stable ... Angina, HFpEF, ... HFrEF, AFib, TAA ... Dissection • CKD, DM ... #pharmacology #table
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Medications Summary Table ... -4 inhibitors SGLT2 ... #medications #table ... endocrinology #dm2
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
resynchronization therapy; DM ... heart failure; HFpEF ... ejection fraction; HFrEF ... Stages #ACCAHA #Algorithm
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
receptor agonist, SGLT2i ... Diabetes #Mellitus #DM2 ... pharmacology #comparison #table
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
functional status - Able ... metabolic equivalent able ... Insulin dependent DM ... event, follow ACC algorithm ... Stable patients